effect of continued weekly subcutaneous semaglutide once‐weekly 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial - Kolotkin - 2023 Semaglutide: Double-edged Sword with Risks

Whilst some have speculated about potential metabolic or anti-inflammatory benefits of Ozempic for endometriosis, there is currently no clinical evidence or regulatory approval supporting this use

It damages the blood vessels and heart, making chest pain more likely

A total of 132 participants (99%) in the semaglutide group and 64 (96%) in the placebo group completed the trial

Yesreal-world effectiveness studies confirm that semaglutide produces 10-15% weight loss at six months in diverse clinic populations when patients maintain consistent dosing and reasonable lifestyle changes

The right peptide can suppress your appetite, accelerate tissue repair, boost growth hormone, or support fat oxidation but it can't create protein from nothing